Comparative utility of aripiprazole and haloperidol in schizophrenia: Post hoc analysis of two 52-week, randomized, controlled trials

Applied Health Economics and Health Policy

Volumn 7, Issue 2, 2009, Pages 109-119

  Kane, John M ^a   Kim, Edward ^b   Kan, Hong J ^b   Guo, Zhenchao ^b   Bates, John A ^b   Whitehead, Richard ^c   Pikalov, Andrei ^c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL;

ADULT; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PARKINSONISM; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HALOPERIDOL; HUMANS; MALE; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 70149093748     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/bf03256145     Document Type: Article

References (26)

1. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guidelines for the treatment of patients with schizophrenia: 2nd ed. Am J Psychiatry 2004; 161 (2 Suppl.): 1-56
2. Lieberman JA. Comparative effectiveness of antipsychotic drugs: A commentary on Cost Utility of the Latest Anti-psychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Arch Gen Psychiatry 2006 Oct; 63 (10): 1069-1072
3. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006 Dec; 163 (12): 2080-2089
4. Geddes J, Freemantle N, Harrison P, et al. Atypical anti-psychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321 (7273): 1371-1376
5. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003 Nov 26; 290 (20): 2693-2702
6. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353 (12): 1209-1223
7. Tiihonen J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006 Jul 29; 333 (7561): 224
8. Stargardt T, Weinbrenner S, Busse R, et al. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. J Ment Health Policy Econ 2008 Jun; 11 (2): 89-97
9. Shumway M, Sentell T, Chouljian T, et al. Assessing preferences for schizophrenia outcomes: comprehension and decision strategies in three assessment methods. Ment Health Serv Res 2003 Sep; 5 (3): 121-135
10. Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004 Nov 1; 71 (1): 155-165
11. Mohr PE, Cheng CM, Claxton K, et al. The heterogeneity of schizophrenia in disease states. Schizophr Res 2004 Nov 1; 71 (1): 83-95
12. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002 Jul; 302 (1): 381-389
13. Jordan S, Koprivica V, Chen R, et al. The antipsychotic ari-piprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol 2002 Apr 26; 441 (3): 137-140
14. Jordan S, Koprivica V, Dunn R, et al. In vivo effects of ar-ipiprazole on cortical and striatal dopaminergic and ser-otonergic function. Eur J Pharmacol 2004; 483 (1): 45-53
15. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63 (9): 763-771
16. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003 Jul; 60 (7): 681-690
17. McEvoy JP, Daniel DG, Carson Jr WH, et al. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007 Dec; 41 (11): 895-905
18. Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 2006 Dec; 189 (2): 259-266
19. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003 Dec; 6 (4): 325-337
20. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or ari-piprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004; 65 (Suppl. 18): 47-56
21. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003 Sep; 64 (9): 1048-1056
22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association, 1994
23. Sachs G, Guille C. Weight gain associated with use of psychotropic medications. J Clin Psychiatry 1999; 60 Suppl. 21: 16-19
24. Fleming T. Red book 2007: ference. 111th ed. Montvale (NJ): Thomson Healthcare, 2007
25. Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophr Res 2005 Nov 15; 79 (2-3): 231-238
26. Buckley PF, Correll CU, Miller AL. First-episode psychosis: a window of opportunity for best practices. CNS Spectr 2007 Sep; 12 (9 Suppl. 15): 1-12